2025
ANIFROLUMAB EFFECTS ON RESPONSE TO INFLUENZA VACCINE IN SLE
Arriens C, Askanase A, Machua W, Koumpouras F, Smith K, Guthridge J, James J, Merrill J. ANIFROLUMAB EFFECTS ON RESPONSE TO INFLUENZA VACCINE IN SLE. The Journal Of Rheumatology 2025, 52: 231-232. DOI: 10.3899/jrheum.2025-0390.pv244.Peer-Reviewed Original ResearchGeometric mean titersResponse to influenza vaccinationStandard-of-care treatmentSLEDAI Flare IndexInfluenza vaccineAdverse eventsVaccine responseSLE patientsHemagglutination inhibitionEnzyme-linked immunosorbent assayWeek 8Anifrolumab groupControl groupContext of influenza vaccinesModerate to severe SLESeasonal influenza virus vaccinesBaseline to week 8Interferon signalingAnti-influenza IgGInfluenza virus vaccineGeometric mean foldDiscontinuation of treatmentHemagglutinin inhibition assayAdult SLE patientsHerpes zoster reactivationOutcomes following single level posterior lumbar fusion in patients with systemic and discoid lupus: A retrospective national database study
Dhodapkar M, Halperin S, Day W, Saifi C, Rubio D, Koumpouras F, Grauer J, Varthi A. Outcomes following single level posterior lumbar fusion in patients with systemic and discoid lupus: A retrospective national database study. North American Spine Society Journal (NASSJ) 2025, 22: 100604. PMID: 40487382, PMCID: PMC12141882, DOI: 10.1016/j.xnsj.2025.100604.Peer-Reviewed Original ResearchPosterior lumbar fusionSystemic lupus erythematosusDiscoid lupus erythematosusSingle-level posterior lumbar fusionPostoperative adverse eventsMinor adverse eventsAdverse eventsIncreased oddsLupus erythematosusLumbar fusionDiagnosis of discoid lupus erythematosusCohort of systemic lupus erythematosusLevel posterior lumbar fusionsMultivariate analysisDiagnosis of systemic lupus erythematosusDiscoid lupus erythematosus patientsUrinary tract infectionPerioperative adverse outcomesSurgical site infectionAcute kidney injuryDeep vein thrombosisNational database studyHistory of infectionSampled adult patientsMultivariate logistic regression
2024
Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus
Salib A, Sanchez J, Huggins L, Seddio A, Dhodapkar M, Smith-Voudouris J, Norman M, Koumpouras F, Grauer J. Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus. Journal Of Shoulder And Elbow Surgery 2024, 34: e196-e204. PMID: 39154846, DOI: 10.1016/j.jse.2024.07.008.Peer-Reviewed Original ResearchSystemic lupus erythematosus patientsSystemic lupus erythematosusTotal shoulder arthroplastyAdverse eventsImplant survivalLupus erythematosusMultivariate analysisShoulder arthroplastyIncreased oddsTotal shoulder arthroplasty patientsNon-SLE patientsMultivariate logistic regressionImmunomodulatory therapyPostoperative complicationsElixhauser Comorbidity IndexAdult patientsNinety-dayUnivariate analysisSurgical planningComorbidity indexPatient counselingGlenohumeral osteoarthritisPatientsComorbid conditionsOrthopedic-related
2015
Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus
Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology 2015, 67: 1848-1857. PMID: 25777546, PMCID: PMC4732716, DOI: 10.1002/art.39108.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAntibodies, Anti-IdiotypicAntigensCarrier ProteinsCholecalciferolCytoskeletal ProteinsDietary SupplementsDNADose-Response Relationship, DrugDouble-Blind MethodFemaleGene Expression RegulationHumansLupus Erythematosus, SystemicMaleMicroarray AnalysisMiddle AgedMyxovirus Resistance ProteinsProspective StudiesRNA-Binding ProteinsVitamin DConceptsPercentage of patientsVitamin D3Vitamin DIFN signatureTreatment groupsSLE patientsInterferon signatureSystemic lupus erythematosus seraDNA antibody levelsVitamin D repletionPlacebo-controlled trialVitamin D deficientVitamin D supplementationVitamin D3 supplementationSubset of patientsSystemic lupus erythematosusD supplementationD deficientD3 supplementationDisease activityImmunologic outcomesInactive diseaseAdverse eventsBaseline characteristicsLupus erythematosus
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply